## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **LISTING OF CLAIMS:**

1. (Previously Presented) A method for inhibiting endothelial cell adhesion, endothelial cell migration and/or angiogenesis, comprising administering to a subject in need thereof an effective amount of:

an isolated peptide comprising an amino acid sequence represented by (I, D, E or K)-(E, A or Q)-L-(L, R or A)-(N, D or S)-(A, L, K or I)-(L or Y)-(R, N, L or K)-(Y or N)-H-(M, I or G)-(V, L, Q or G)-(G, K, T or D)-(R, S, L or E)-(R, A, E or I)-(V, M, T or L)-(L, C or V)-(T, A, G or S).

## 2-3. (Canceled).

- 4. (Previously Presented). The method of Claim 1, wherein the isolated peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 23 to SEQ ID NO: 26.
- 5. (Previously Presented) The method of Claim 1, wherein the isolated peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 17 to SEQ ID NO: 22.
- 6. (Previously Presented) The method of Claim 5, wherein the isolated peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 11 to SEQ ID NO: 16.
- 7. (Currently Amended) A method for the treatment of an angiogenesis-related disease, comprising administering to a subject in need thereof an effective amount of: an isolated peptide comprising an amino acid sequence represented by (I, D, E or

K)-(E, A or Q)-L-(L, R or A)-(N, D or S)-(A, L, K or I)-(L or Y)-(R, N, L or K)-(Y or N)-H-

(M, I or G)-(V, L, Q or G)-(G, K, T or D)-(R, S, L or E)-(R, A, E or I)-(V, M, T or L)-(L, C or V)-(T, A, G or S), wherein:

the angiogenesis-related disease is selected from the group consisting of: cancer, vascular malformation, arteriosclerosis, vascular adhesions, edematous sclerosis, corneal graft neovascularization, neovascular glaucoma, diabetic retinopathy, pterygium, retinal degeneration, retrolental fibroplasia, granular conjunctivitis, and rheumatoid arthritis, systemic Lupus erythematosus, thyroiditis, psoriasis, pyogenic granuloma, seborrheic dermatitis and acne.

## 8-12. (Canceled).

- 13. (Previously Presented). The method of Claim 7, wherein the isolated peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 23 to SEQ ID NO: 26.
- 14. (Previously Presented) The method of Claim 7, wherein the isolated peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 17 to SEQ ID NO: 22.
- 15. (Previously Presented) The method of Claim 7, wherein the isolated peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 11 to SEQ ID NO: 16.
- 16. (New) The method of claim 7, wherein the angiogenesis-related disease is cancer.
- 17. (New) The method of claim 7, wherein the angiogenesis-related disease is rheumatoid arthritis.